Artelo Biosciences (ARTL) Q3 2024 earnings summary

Executive summary

• The company is a clinical-stage biopharmaceutical firm developing therapeutics targeting lipid-signaling pathways, with a pipeline including synthetic cannabinoid and FABP5 inhibitor programs in oncology, pain, and anxiety.

• ART27.13 is in a Phase 1b/2a trial for cancer-related anorexia, with full Phase 2a enrollment expected by late 2024 or early 2025; ART26.12, a FABP5 inhibitor, is set to begin Phase 1 trials in Q4 2024, with results expected in H1 2025.

• ART12.11 clinical trials for anxiety and depression are planned for 2025.

• No revenue has been generated to date; operations are funded through equity offerings and an equity line with an institutional investor.

• Multiple clinical readouts are anticipated over the next 15 months, including for ART26.12 and ART27.13.

Financial highlights

• Net loss for the three months ended September 30, 2024, was $1.1 million ($0.35 per share), improved from $2.4 million ($0.83 per share) in the same quarter last year.

• Operating expenses for the quarter were $1.2 million, down from $2.6 million year-over-year, mainly due to increased UK R&D tax credits and lower stock-based compensation.

• Cash, cash equivalents, and investments totaled $4.9 million as of September 30, 2024, down from $11.0 million at year-end 2023.

• R&D expenses were $0.3 million, down from $1.6 million year-over-year; general and administrative expenses were $0.9 million, compared to $1.0 million prior year.

• Received $1.3 million R&D tax credit from the UK government for qualified prior research expenses.

Outlook and guidance

• Existing cash resources are expected to fund planned operations into Q4 2025; additional capital will be required to continue operations beyond that period.

• ART27.13 Phase 2a enrollment is projected to complete by late 2024 or early 2025; ART26.12 Phase 1 trials are expected to commence in Q4 2024, with results in H1 2025.

• ART12.11 clinical trials for anxiety and depression are planned for 2025.

• The company anticipates increased expenses as it advances clinical programs and expands its intellectual property portfolio.

• Multiple clinical trial readouts are anticipated over the next 15 months.